Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13965835 | 0.87 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL1659835 | 0.83 | ALDH1A1 (0.71) | ALDH1A1CYP3A4CYP2D6CYP2C19CHRM2 | |
| SCHEMBL16522409 | 0.82 | MAOA (0.68) | CHRM2MAOAMAPTSIGMAR1 | |
| SCHEMBL13509693 | 0.81 | CHRM2 (0.71) | ALDH1A1CYP2D6CHRM2 | |
| SCHEMBL372804 | 0.81 | MAOA (0.71) | CHRM2MAOASIGMAR1 | |
| SCHEMBL29380563 | 0.81 | MAOA (0.71) | CHRM2MAOASIGMAR1 | |
| SCHEMBL26375519 | 0.81 | CHRM2 (0.50) | CYP2D6CYP2C19CHRM2MAOAHRH4 | |
| SCHEMBL640522 | 0.81 | MAOA (0.71) | CHRM2MAOASIGMAR1 | |
| SCHEMBL7861380 | 0.81 | MAOA (0.71) | CHRM2MAOASIGMAR1 | |
| SCHEMBL6900998 | 0.81 | MAOA (0.71) | CHRM2MAOASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8338448-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338448-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2009121063-A2 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172330-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | ALDH1A1 2030/4885CYP3A4 2009/4885CYP2D6 2232/4885 |
| US-20100029634-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | ALDH1A1 2030/4885CYP3A4 2009/4885CYP2D6 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.